MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK gene rearrangements as they are in clinical studies—even though randomized trials “cherry …
COPENHAGEN—Longer progression free survival (PFS) was achieved in patients with ALK-rearranged non-small cell lung cancer (NSCLC) previously treated with crizotinib randomised to treatment with the second generation anaplastic lymphoma kinase (ALK) inhibitor ceritinib rather than chemotherapy in the phase 3 …
LONDON, UK—Whole brain radiotherapy brought no benefit to patients whose non-small cell lung cancer had metastasized to the brain in research findings published in The Lancet and presented at the European Respiratory Society (ERS) 2016 Congress held in London (3-7 …